Payment overview · 2025
General Payments
$1,785.42
74 reported records · 25 companies
Healthcare provider profile · identity verified
Mark Samuel Thomas Armitage, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WILMINGTON, NC · NPI 1912952847
Verified facts
What the public records show
CMS Open Payments records show Mark Samuel Thomas Armitage, M.D. received $1,785.42 in general payments during 2025 across 74 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Nurtec Odt, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nurtec Odt by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $455.34 | 25.5% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $173.42 | 9.7% | 15 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $112.03 | 6.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $108.74 | 6.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $104.34 | 5.8% | 6 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $94.44 | 5.3% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $82.88 | 4.6% | 5 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $63.63 | 3.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $54.73 | 3.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.70 | 3.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $53.31 | 3.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $52.17 | 2.9% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.24 | 2.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $45.09 | 2.5% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$40.18 | 2.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $36.87 | 2.1% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.25 | 2.0% | 2 | 2025 |
| Dynasplint Systems Inc. | Unresolved — no canonical attribution shown | $35.42 | 2.0% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $27.16 | 1.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.30 | 1.4% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $20.38 | 1.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.82 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.84 | 0.9% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.21 | 0.9% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $13.93 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,785.42 | 74 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $174.36 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $161.16 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $148.41 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $147.63 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $112.03 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $98.34 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $94.44 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $82.88 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $55.64 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $54.73 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $54.73 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $53.70 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $53.31 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $52.17 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $45.09 | 2 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $40.18 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $38.83 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.32 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $36.87 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $36.25 | 2 | 2025 |
Source payment records
|
|||||
| Dynasplint Normalized: dynasplint |
Device | Dynasplint Systems Inc. | $35.42 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $27.16 | 1 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $27.15 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.01 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| SIMPLIMAX Normalized: simplimax |
Medical Supply | Organogenesis Inc. | $22.87 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| VIA MATRIX Normalized: via matrix |
Medical Supply | Organogenesis Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $2.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 55 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 50 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 45 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
55 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | 21 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
55 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 464 | 138 |
| Atorvastatin Calcium | Atorvastatin Calcium | 463 | 138 |
| Losartan Potassium | Losartan Potassium | 444 | 151 |
| Amlodipine Besylate | Amlodipine Besylate | 327 | 101 |
| Gabapentin | Gabapentin | 325 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 319 | 103 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 273 | 80 |
| Metformin Hcl | Metformin Hcl | 255 | 85 |
| Furosemide | Furosemide | 230 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 224 | 75 |
| Famotidine | Famotidine | 192 | 56 |
| Trazodone Hcl | Trazodone Hcl | 179 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 174 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 167 | 40 |
| Omeprazole | Omeprazole | 136 | 50 |
| Potassium Chloride | Potassium Chloride | 121 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 42 |
| Buspirone Hcl | Buspirone Hcl | 118 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 112 | 33 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 109 | 41 |
| Meloxicam | Meloxicam | 105 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 31 |
| Spironolactone | Spironolactone | 94 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 32 |
| Alendronate Sodium | Alendronate Sodium | 83 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 82 | 60 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 81 | 30 |
| Simvastatin | Simvastatin | 81 | 27 |
| Ozempic | Semaglutide | 80 | 19 |
| Sertraline Hcl | Sertraline Hcl | 79 | 32 |
| Carvedilol | Carvedilol | 77 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 24 |
| Montelukast Sodium | Montelukast Sodium | 66 | 25 |
| Prednisone | Prednisone | 65 | 40 |
| Mirtazapine | Mirtazapine | 64 | 11 |
| Aripiprazole | Aripiprazole | 62 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 19 |
| Metformin Hcl Er | Metformin Hcl | 58 | 25 |
| Eliquis | Apixaban | 55 | 18 |
| Linzess | Linaclotide | 55 | 18 |
| Vascepa | Icosapent Ethyl | 53 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | suppressed |
| Celecoxib | Celecoxib | 51 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 40 |
| Valsartan | Valsartan | 51 | 15 |
| Jardiance | Empagliflozin | 50 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 17 |
| Indomethacin | Indomethacin | 47 | 14 |
| Lisinopril | Lisinopril | 46 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 16 |
| Mounjaro | Tirzepatide | 45 | 12 |
| Donepezil Hcl | Donepezil Hcl | 44 | 11 |
| Valacyclovir | Valacyclovir Hcl | 44 | 24 |
| Ibuprofen | Ibuprofen | 43 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 43 | 12 |
| Allopurinol | Allopurinol | 42 | 15 |
| Januvia | Sitagliptin Phosphate | 41 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 11 |
| Cefdinir | Cefdinir | 38 | 31 |
| Repatha Sureclick | Evolocumab | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 13 |
| Doxepin Hcl | Doxepin Hcl | 36 | suppressed |
| Atenolol | Atenolol | 35 | 11 |
| Baclofen | Baclofen | 35 | suppressed |
| Ezetimibe | Ezetimibe | 35 | 12 |
| Fluconazole | Fluconazole | 35 | 31 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | 12 |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 12 |
| Promethazine Hcl | Promethazine Hcl | 34 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Finasteride | Finasteride | 32 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | 11 |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 13 |
| Glipizide | Glipizide | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 25 |
| Terbinafine Hcl | Terbinafine Hcl | 28 | 13 |
| Irbesartan | Irbesartan | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | 13 |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 20 |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Misoprostol | Misoprostol | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 15 |
| Topiramate | Topiramate | 23 | suppressed |
| Cephalexin | Cephalexin | 21 | 17 |
| Clonazepam | Clonazepam | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 17 |
| Nystatin | Nystatin | 21 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,785.42 · 74 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APLIGRAF, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dynasplint, ELIQUIS, FARXIGA, GEMTESA, IBSRELA, INCEPTIV, JARDIANCE, MOUNJARO, NEXLETOL, NURTEC ODT, NUZYRA, OPSUMIT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SIMPLIMAX, SPRAVATO, TZIELD, UBRELVY, UPTRAVI, UZEDY, VIA MATRIX, VOQUEZNA, VRAYLAR, Veozah, XIFAXAN, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error